Navigating Cannabis Use in Health Care Settings | ASHP Midyear
Drug Topics
DECEMBER 8, 2024
Navigating Cannabis use requires more than just an understanding of the endocannabinoid system.
Sun.Dec 08, 2024
185 
ASHP: Identify and Counsel Patients at High Risk for Severe COVID-19
Pharmacy Times
DECEMBER 8, 2024
By identifying patients at high risk for progressing to severe disease and counseling them on their treatment options, pharmacists empower patients to make informed decisions about their treatment.
Join 5,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
STAT+: Pfizer’s abrupt withdrawal of sickle cell drug Oxbryta called ‘tone deaf’ at ASH conference
STAT
DECEMBER 8, 2024
SAN DIEGO — Pfizer’s abrupt withdrawal of its sickle cell drug Oxybryta over safety concerns was called “tone deaf” during a panel discussion among sickle cell experts Saturday at STAT@ASH , which took place during the American Society of Hematology’s annual meeting. They said patients were despondent over how suddenly the drug was pulled from the market in September because there had been no clear indication of problems in advance of the announcement.
ASHP Midyear: Opioid Use Disorder in Critically Ill Patients Has Unique Challenges
Pharmacy Times
DECEMBER 8, 2024
In hospital and critical care settings, pharmacists can play a significant role in educating other health care providers about treatment options, proper dosing, and more.
From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
STAT+: BIOSECURE Act, aimed at Chinese drug manufacturers, is dealt a major blow
STAT
DECEMBER 8, 2024
WASHINGTON — Legislation to restrict U.S. drugmakers from using key Chinese contract manufacturers was dealt a major blow when senators left it out of a must-pass defense budget bill this weekend. The BIOSECURE Act would prohibit pharmaceutical and biotechnology companies from using services or equipment from Chinese “companies of concern,” including WuXi AppTec and WuXi Biologics, in work that is contracted or funded by the U.S. federal government.
Fixed-Duration Acalabrutinib and Venetoclax Regimens Redefine First-Line Treatment Options for Patients With CLL
Pharmacy Times
DECEMBER 8, 2024
The phase 3 AMPLIFY trial demonstrates that fixed-duration regimens of acalabrutinib and venetoclax, with or without obinutuzumab, significantly improve progression-free survival and deliver manageable safety profiles compared to chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia (CLL).
Signup to get articles personalized to your interests!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
More Trending
ASH 2024: Rapid Uptake of Bispecific Antibodies for R/R Multiple Myeloma Observed in Community Oncology Settings
Pharmacy Times
DECEMBER 8, 2024
Ira Zackon, MD explains his analysis of bispecific antibody utilizaton for relapsed or refractory multiple myeloma in community oncology centers.
Biopharma leaders lay out vision for the future of blood cancer treatment
STAT
DECEMBER 8, 2024
(This roundup of news from the ASH 2024 conference first appeared in STAT’s “ASH in 30” newsletter. To get future editions, sign up here.) When in San Diego, eat tacos. Amazing. Adam, Jonathan, Meghana, and Angus are back for your Sunday ASH rundown. And thanks to everyone who packed the room last night for our STAT @ ASH event.
ASH 2024: New Treatments in Trial Pipeline Show Promising Survival Rates in R/R Multiple Myeloma
Pharmacy Times
DECEMBER 8, 2024
Robert Rifkin, MD, FACP, discusses multiple abstracts featuring drugs demonstrating efficacy in patients with relapsed/refractory multiple myeloma.
Study paints clearer picture of disadvantaged leukemia patients’ struggle to get bone marrow transplants
STAT
DECEMBER 8, 2024
SAN DIEGO — Bone marrow transplants can be lifesaving for patients with acute myeloid leukemia, but new research reveals how socioeconomic factors create barriers to treatment and higher death rates for people living in disadvantaged communities. A scientific team led by researchers at Fred Hutchinson Cancer Center tracked AML patients across academic and community treatment centers.
Position Your Pharmacy for Expansion
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
ASHP Midyear: Pharmacists Play Key Role in Optimizing Continuous Glucose Monitoring for Diabetes Management
Pharmacy Times
DECEMBER 8, 2024
Pharmacists can leverage continuous glucose monitoring data to personalize diabetes management, overcome clinical inertia, and improve glycemic control for patients.
The Sighing Christian
The Honest Apothecary
DECEMBER 8, 2024
Rejoicing is a Christian duty and privilege. In fact, it is to be a perpetual ornament of the character of every believer in Christ Jesus. “Rejoice in the Lord always”, says Paul to the Philippians in chapter 4:4 of that epistle, “and again I say, rejoice!” And there is much for us to be joyful […] The post The Sighing Christian appeared first on The Honest Apothecary.
Daratumumab Demonstrates Significant Benefit in High-Risk Smoldering Myeloma: Results from the Phase 3 AQUILA Study
Pharmacy Times
DECEMBER 8, 2024
The AQUILA study demonstrates that early treatment with daratumumab significantly delays progression to symptomatic multiple myeloma, improves survival outcomes, and offers a well-tolerated alternative to traditional observation.
WHO sheds some light on factors possibly at play in DRC outbreak
STAT
DECEMBER 8, 2024
The cause of an outbreak of illness in a remote part of the Democratic Republic of the Congo that has garnered substantial international attention is still not known. But a statement released Sunday by the World Health Organization both sheds some light on why the source of the illness hasn’t yet been identified and what the illness — or illnesses — might be.
What the FDA's New Dosage Guidance Means for the Future of Clinical Research
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
ASH: Zanubrutinib Demonstrates Long-Term Efficacy in Patients With Waldenström Macroglobulinemia
Pharmacy Times
DECEMBER 8, 2024
Shirley D'Sa, MD, highlights the long-term efficacy and tolerability of zanubrutinib in patients with Waldenstrm macroglobulinemia, as seen in the long-term extension of ASPEN.
Trump suggests he shares some of RFK Jr.’s concerns about childhood vaccines
STAT
DECEMBER 8, 2024
President-elect Donald Trump suggested in a television interview on Sunday that he shares some of the concerns voiced by Robert F. Kennedy Jr., his choice to be secretary of health and human services, about the safety of some common childhood vaccines. The comments, made on NBC’s Meet the Press , represent an increased sign of support for RFK Jr. taking action on that topic if he is confirmed by the Senate.
ASHP Midyear: Expert Highlights New Non-Statin Medication and Combination Therapy Strategies
Pharmacy Times
DECEMBER 8, 2024
Both statins and newer non-statin medications are important in combination to effectively lower atherogenic lipid levels and reduce cardiovascular risk.
Let's personalize your content